1201 Quick Takes
BioCentury & Getty Images

Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports 

Dec 2, 2020 | 2:32 AM GMT

Blueprint gains broader FDA label for Gavreto
FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at

Read the full 579 word article

How to gain access

Continue reading with a
two-week free trial.